AI in Healthcare

Today's Stories

1. 1

   Pfizer partners with AI startup Chai Discovery to speed up drug development

   Pfizer signed a licensing agreement with Chai Discovery to use the startup's AI software for designing antibodies and discovering new drugs. The AI can predict how proteins fold and interact, which traditionally takes years of lab work to figure out.

   This could lead to new medicines reaching patients faster, as AI can test thousands of drug combinations digitally before expensive lab trials begin.

2. 2

   Eli Lilly invests in Abridge to expand AI beyond doctor's notes

   Pharmaceutical giant Eli Lilly invested in Abridge, an AI company valued at $5.3 billion that automatically transcribes and summarizes doctor-patient conversations. Abridge is now expanding beyond clinical notes into billing, drug trials, and real-time insurance claims processing.

   Patients may soon experience faster insurance approvals and less paperwork during medical visits, as AI handles administrative tasks automatically.

3. 3

   Japanese drugmaker Nxera joins global AI research consortium for medicine

   Nxera Pharma joined OpenFold, a nonprofit research group that develops open-source AI tools for biology and drug discovery. The consortium includes tech giants like Amazon, Microsoft, and NVIDIA alongside numerous pharmaceutical companies worldwide.

   This collaboration could accelerate the development of new treatments as companies share AI research instead of each working in isolation.

4. 4

   AI drug discovery leaders warn against U.S. funding cuts

   Executives from companies like Lila Sciences and NVIDIA warned that proposed cuts to U.S. health research funding could allow other countries to surpass America in AI-powered drug development. They argue that the combination of AI and biology will determine global competitiveness for decades.

   Reduced funding could mean fewer breakthrough medicines are developed in the U.S., potentially affecting which treatments become available to American patients first.